Physician profile
Javier Kamisato
NPI 1902943434
$11,576.00
in general payments reported to CMS, 2019-2025
34 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $1,093 · 2021: $2,581 · 2022: $1,217 · 2023: $2,068 · 2024: $2,187 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,524 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,523.89 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,953.43 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $1,472.16 | 2021 | |
| Amgen INC. | $1,209.50 | 2019-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $736.14 | 2020-2025 | |
| Amarin Pharma, INC. | $611.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $467.53 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $466.54 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $390.56 | 2022-2023 | Fanapt, Hetlioz |
| Radius Health, INC. | $344.33 | 2020-2024 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $324.12 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $291.11 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.24 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $258.91 | 2019-2023 | Arexvy |
| Lilly USA, LLC | $236.41 | 2020-2024 | Emgality, Mounjaro, Reyvow |
| Merck Sharp & Dohme LLC | $146.02 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $143.73 | 2024 | Injectafer |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.97 | 2022 | |
| Phathom Pharmaceuticals, INC. | $120.91 | 2024 | Voquezna |
| Mannkind Corporation | $101.63 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $99.39 | 2019-2020 | |
| Silk Road Medical, INC. | $96.97 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Recordati_rare_diseases_inc. | $87.67 | 2025 | Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.52 | 2020-2021 | |
| Bausch Health US, LLC | $77.75 | 2022-2023 | Aplenzin, Wellbutrin |
| Genentech USA, INC. | $70.96 | 2019-2021 | |
| Pfizer INC. | $53.53 | 2024 | |
| Novartis Pharmaceuticals Corporation | $49.90 | 2022-2024 | |
| Abbott Laboratories | $42.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.57 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.47 | 2023 | Evkeeza |
| Alexion Pharmaceuticals, INC. | $21.43 | 2020 | |
| Allergan, INC. | $13.53 | 2020 | |
| Dexcom, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Kamisato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.